Roivant Sciences Ltd | Mid-cap | Healthcare
$10.94
-2.93%
| Roivant Sciences Stock Comparison:
Roivant Sciences vs VertexRoivant Sciences vs RegeneronRoivant Sciences vs Blueprint MedicinesRoivant Sciences vs Bio-TechneRoivant Sciences vs Revolution MedicinesRoivant Sciences vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2025

Income Metrics

Revenue 29.1M
Gross Profit 28.1M 96.86%
Operating Income -1.1B -3,833.27%
Net Income -356.7M -1,227.87%

Balance Sheet Metrics

Shareholders Equity 5.2B
Debt to Equity 0.00

Cash Flow Metrics

Operating Cash Flow -18.2M

Revenue & Profitability Trend

Roivant Sciences Income Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Revenue 29.1M 124.8M 61.3M 55.3M 23.8M
Cost of Goods Sold 911.0K 15.6M 13.1M 9.0M 2.1M
Gross Profit 28.1M 109.2M 48.2M 46.3M 21.7M
Research & Development 550.4M 501.7M 525.2M 483.0M 236.6M
Selling, General & Administrative 591.4M 687.4M 600.5M 775.0M 259.9M
Other Operating Expenses 0 0 0 0 0
Total Operating Expenses 1.1B 1.2B 1.1B 1.3B 496.5M
Operating Income -1.1B -1.1B -1.1B -1.2B -474.8M
Pre-tax Income -681.6M 4.3B -1.2B -923.7M -898.5M
Income Tax 48.2M 22.2M 5.2M 369.0K 1.7M
Net Income -356.7M 4.2B -1.1B -924.1M -900.2M
EPS (Diluted) - $5.23 -$1.42 -$1.26 -$1.18

Income Statement Trend

Roivant Sciences Balance Sheet From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Assets
Current Assets - 6.7B 1.8B 2.1B 2.2B
Non-Current Assets - 490.7M 591.0M 438.6M 402.7M
Total Assets - 7.2B 2.4B 2.6B 2.6B
Liabilities
Current Liabilities - 266.8M 272.4M 184.4M 219.0M
Non-Current Liabilities - 507.2M 509.6M 339.3M 308.7M
Total Liabilities - 774.0M 782.0M 523.7M 527.7M
Equity
Total Shareholders Equity 5.2B 6.4B 1.6B 2.1B 2.1B

Balance Sheet Composition

Roivant Sciences Cash Flow Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Operating Activities
Net Income - 4.2B -1.1B -924.1M -900.2M
Operating Cash Flow -18.2M 4.5B -889.2M -305.3M -354.2M
Investing Activities
Capital Expenditures - -1.4M -12.7M -17.4M -5.8M
Investing Cash Flow - 5.2B -44.3M 303.3M -31.7M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow - 364.1M 496.3M 306.4M 456.3M
Free Cash Flow - -766.6M -856.1M -695.2M -557.9M

Cash Flow Trend

Roivant Sciences Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 1.95
Forward P/E -9.66
Price to Book 1.71
Price to Sales 269.09
PEG Ratio -9.66

Profitability Ratios

Profit Margin 96.86%
Operating Margin -4,823.84%
Return on Equity -12.54%
Return on Assets -10.73%

Financial Health

Current Ratio 33.46
Debt to Equity 1.93
Beta 1.16

Per Share Data

EPS (TTM) -$0.75
Book Value per Share $6.74
Revenue per Share $0.04

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
roiv 7.8B 1.95 1.71 -12.54% 96.86% 1.93
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Blueprint Medicines 8.3B -120.00 24.19 -47.71% -27.70% 208.50
Bio-Techne 7.9B 60.87 3.92 6.53% 10.89% 20.99
Revolution Medicines 7.5B -11.18 3.59 -36.68% 0.00% 6.46

Financial data is updated regularly. All figures are in the company's reporting currency.